AR063345A1 - N-(2-hidroxietil)-n-metil-4-(quinolin-8-il(1-(tiazol-4-ilmetil)-piperidin-4-iliden)metil) benzamida para el tratamiento del dolor, ansiedad y depresion - Google Patents
N-(2-hidroxietil)-n-metil-4-(quinolin-8-il(1-(tiazol-4-ilmetil)-piperidin-4-iliden)metil) benzamida para el tratamiento del dolor, ansiedad y depresionInfo
- Publication number
- AR063345A1 AR063345A1 ARP070104641A ARP070104641A AR063345A1 AR 063345 A1 AR063345 A1 AR 063345A1 AR P070104641 A ARP070104641 A AR P070104641A AR P070104641 A ARP070104641 A AR P070104641A AR 063345 A1 AR063345 A1 AR 063345A1
- Authority
- AR
- Argentina
- Prior art keywords
- methyl
- quinolin
- benzamide
- piperidin
- hydroxyethyl
- Prior art date
Links
- -1 2-HYDROXYETHYL Chemical class 0.000 title abstract 4
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 title abstract 4
- 208000019901 Anxiety disease Diseases 0.000 title 1
- 230000036506 anxiety Effects 0.000 title 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 title 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86232706P | 2006-10-20 | 2006-10-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR063345A1 true AR063345A1 (es) | 2009-01-21 |
Family
ID=39314285
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070104641A AR063345A1 (es) | 2006-10-20 | 2007-10-19 | N-(2-hidroxietil)-n-metil-4-(quinolin-8-il(1-(tiazol-4-ilmetil)-piperidin-4-iliden)metil) benzamida para el tratamiento del dolor, ansiedad y depresion |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US7659286B2 (OSRAM) |
| EP (1) | EP2079735B1 (OSRAM) |
| JP (1) | JP4668346B2 (OSRAM) |
| KR (1) | KR20090065534A (OSRAM) |
| CN (1) | CN101528739B (OSRAM) |
| AR (1) | AR063345A1 (OSRAM) |
| AT (1) | ATE543818T1 (OSRAM) |
| AU (2) | AU2007313515B2 (OSRAM) |
| BR (1) | BRPI0717631A2 (OSRAM) |
| CA (1) | CA2667041C (OSRAM) |
| CL (1) | CL2007003009A1 (OSRAM) |
| CO (1) | CO6180450A2 (OSRAM) |
| CY (1) | CY1112718T1 (OSRAM) |
| DK (1) | DK2079735T3 (OSRAM) |
| ES (1) | ES2379519T3 (OSRAM) |
| HR (1) | HRP20120344T1 (OSRAM) |
| IL (1) | IL197876A0 (OSRAM) |
| MX (1) | MX2009003974A (OSRAM) |
| MY (1) | MY148880A (OSRAM) |
| NO (1) | NO20091969L (OSRAM) |
| NZ (1) | NZ577060A (OSRAM) |
| PE (2) | PE20080892A1 (OSRAM) |
| PL (1) | PL2079735T3 (OSRAM) |
| PT (1) | PT2079735E (OSRAM) |
| RS (1) | RS52260B (OSRAM) |
| RU (1) | RU2454414C2 (OSRAM) |
| SA (1) | SA07280549B1 (OSRAM) |
| SI (1) | SI2079735T1 (OSRAM) |
| TW (1) | TW200826939A (OSRAM) |
| UA (1) | UA97648C2 (OSRAM) |
| UY (1) | UY30652A1 (OSRAM) |
| WO (1) | WO2008048171A1 (OSRAM) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1641757A1 (en) * | 2003-05-16 | 2006-04-05 | AstraZeneca AB | Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof |
| MY148880A (en) | 2006-10-20 | 2013-06-14 | Astrazeneca Ab | N-(2-hydroxyethyl)-n-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl)benzamide, the process of making it as well as its use for the treatment of pain, anxiety and depression |
| BRPI0912756A2 (pt) * | 2008-05-20 | 2015-10-13 | Astrazeneca Ab | método para tratar transtorno depressivo maior ansioso em um animal de sangue quente, uso de um composto, composto, e, composição farmacêutica |
| CN101906078B (zh) * | 2009-06-08 | 2012-02-01 | 上海威智医药科技有限公司 | 噻唑衍生物的合成方法 |
| CN102106807B (zh) * | 2009-12-29 | 2013-03-27 | 上海中西制药有限公司 | 一种固体制剂的制备方法及所得固体制剂 |
| WO2016099393A1 (en) * | 2014-12-19 | 2016-06-23 | Pharmnovo Ab | Diarylmethylidene piperidine derivatives and their use as delta opioid receptor agonists |
| EP3853435B1 (en) | 2018-09-21 | 2024-08-21 | Garland Industries, Inc. | Helical hardbanding |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2898339A (en) * | 1957-07-29 | 1959-08-04 | Wm S Merrell Co | N-substituted benzhydrol, benzhydryl, and benzhydrylidene piperidine |
| US4581171A (en) * | 1983-07-27 | 1986-04-08 | Janssen Pharmaceutica, N.V. | [[Bis(aryl)methylene]-1-piperidinyl]alkyl-pyrimidinones useful for treating psychotropic disorders |
| TW548271B (en) * | 1996-12-20 | 2003-08-21 | Astra Pharma Inc | Novel piperidine derivatives having an exocyclic double bond with analgesic effects |
| AU2009799A (en) * | 1997-12-24 | 1999-07-19 | Ortho-Mcneil Pharmaceutical, Inc. | 4-(aryl(piperidin-4-yl)) aminobenzamides which bind to the delta-opioid receptor |
| US6492375B2 (en) * | 1998-06-30 | 2002-12-10 | Neuromed Technologies, Inc. | Partially saturated calcium channel blockers |
| SE9904673D0 (sv) * | 1999-12-20 | 1999-12-20 | Astra Pharma Inc | Novel compounds |
| AU784848B2 (en) | 1999-12-20 | 2006-07-06 | Zalicus Pharmaceuticals Ltd. | Partially saturated calcium channel blockers |
| CN1426411A (zh) * | 2000-03-03 | 2003-06-25 | 奥索-麦克尼尔药品公司 | 3－(二芳基亚甲基)－8－氮杂双环[3.2.1]辛烷衍生物 |
| SE0001208D0 (sv) * | 2000-04-04 | 2000-04-04 | Astrazeneca Canada Inc | Novel compounds |
| SE0101768D0 (sv) * | 2001-05-18 | 2001-05-18 | Astrazeneca Ab | Novel compounds |
| US20040204404A1 (en) * | 2002-09-30 | 2004-10-14 | Robert Zelle | Human N-type calcium channel blockers |
| SE0300105D0 (sv) * | 2003-01-16 | 2003-01-16 | Astrazeneca Ab | Diarylmethylidene piperdine derivatives, preparations thereof and uses thereof |
| SE0301444D0 (sv) * | 2003-05-16 | 2003-05-16 | Astrazeneca Ab | Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof |
| SE0301442D0 (sv) * | 2003-05-16 | 2003-05-16 | Astrazeneca Ab | Diarylmethylidene piperidine derivatives, preparations therof and uses thereof |
| EP1641757A1 (en) * | 2003-05-16 | 2006-04-05 | AstraZeneca AB | Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof |
| SE0301445D0 (sv) * | 2003-05-16 | 2003-05-16 | Astrazeneca Ab | Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof |
| SE0301441D0 (sv) * | 2003-05-16 | 2003-05-16 | Astrazeneca Ab | Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof |
| SE0400025D0 (sv) * | 2004-01-09 | 2004-01-09 | Astrazeneca Ab | Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof |
| WO2005087742A1 (en) | 2004-03-08 | 2005-09-22 | Exelixis, Inc. | Metabolic kinase modulators and methods of use as pesticides |
| MY148880A (en) * | 2006-10-20 | 2013-06-14 | Astrazeneca Ab | N-(2-hydroxyethyl)-n-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl)benzamide, the process of making it as well as its use for the treatment of pain, anxiety and depression |
-
2007
- 2007-10-09 MY MYPI20091593A patent/MY148880A/en unknown
- 2007-10-18 TW TW096139052A patent/TW200826939A/zh unknown
- 2007-10-19 KR KR1020097007893A patent/KR20090065534A/ko not_active Ceased
- 2007-10-19 WO PCT/SE2007/000924 patent/WO2008048171A1/en not_active Ceased
- 2007-10-19 CN CN2007800390975A patent/CN101528739B/zh not_active Expired - Fee Related
- 2007-10-19 ES ES07835125T patent/ES2379519T3/es active Active
- 2007-10-19 PE PE2007001423A patent/PE20080892A1/es not_active Application Discontinuation
- 2007-10-19 US US11/875,014 patent/US7659286B2/en not_active Expired - Fee Related
- 2007-10-19 HR HRP20120344TT patent/HRP20120344T1/hr unknown
- 2007-10-19 SI SI200730905T patent/SI2079735T1/sl unknown
- 2007-10-19 CA CA2667041A patent/CA2667041C/en not_active Expired - Fee Related
- 2007-10-19 AR ARP070104641A patent/AR063345A1/es not_active Application Discontinuation
- 2007-10-19 PL PL07835125T patent/PL2079735T3/pl unknown
- 2007-10-19 AU AU2007313515A patent/AU2007313515B2/en not_active Ceased
- 2007-10-19 CL CL200703009A patent/CL2007003009A1/es unknown
- 2007-10-19 DK DK07835125.1T patent/DK2079735T3/da active
- 2007-10-19 UY UY30652A patent/UY30652A1/es not_active Application Discontinuation
- 2007-10-19 UA UAA200903085A patent/UA97648C2/ru unknown
- 2007-10-19 BR BRPI0717631-7A patent/BRPI0717631A2/pt not_active IP Right Cessation
- 2007-10-19 EP EP07835125A patent/EP2079735B1/en active Active
- 2007-10-19 AT AT07835125T patent/ATE543818T1/de active
- 2007-10-19 JP JP2009533278A patent/JP4668346B2/ja not_active Expired - Fee Related
- 2007-10-19 PT PT07835125T patent/PT2079735E/pt unknown
- 2007-10-19 NZ NZ577060A patent/NZ577060A/en not_active IP Right Cessation
- 2007-10-19 RU RU2009111337/04A patent/RU2454414C2/ru not_active IP Right Cessation
- 2007-10-19 RS RS20120166A patent/RS52260B/sr unknown
- 2007-10-19 MX MX2009003974A patent/MX2009003974A/es active IP Right Grant
- 2007-10-20 SA SA7280549A patent/SA07280549B1/ar unknown
-
2009
- 2009-03-26 IL IL197876A patent/IL197876A0/en unknown
- 2009-03-31 CO CO0903310009033100A patent/CO6180450A2/es not_active Application Discontinuation
- 2009-05-20 NO NO20091969A patent/NO20091969L/no not_active Application Discontinuation
- 2009-12-21 US US12/643,202 patent/US7977355B2/en not_active Expired - Fee Related
-
2010
- 2010-10-06 AU AU2010226996A patent/AU2010226996A1/en not_active Abandoned
-
2012
- 2012-04-25 CY CY20121100389T patent/CY1112718T1/el unknown
- 2012-07-24 PE PE2012001060A patent/PE20140634A1/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR063345A1 (es) | N-(2-hidroxietil)-n-metil-4-(quinolin-8-il(1-(tiazol-4-ilmetil)-piperidin-4-iliden)metil) benzamida para el tratamiento del dolor, ansiedad y depresion | |
| CL2020002056A1 (es) | Formas cristalinas novedosas. | |
| CL2008002162A1 (es) | Compuestos derivados de 3-benzoisoxazol-piperidin; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento y/o prevencion de trastornos cognitivos, adiccion a drogas, depresion, ansiedad, entre otras. | |
| CL2008002998A1 (es) | Compuestos derivados de piperazina-1-carboxamida, inhibidor de faah; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del dolor inflamatorio o neuropatico, ansiedad y depresion. | |
| CL2008002622A1 (es) | 1-(1-metiletil)-4-{[4-(tetrahidro-2h-piran-4-iloxi)fenil]carbonil}piperazina y su sal hidrocloruro; formas cristalinas de la sal; proceso de preparacion; composicion farmaceutica; y uso para el tratamiento o profilaxis de deterioro cognitivo, fatiga o trastorno del sueno. | |
| UY30779A1 (es) | Derivados de dihidropiridina de utilidad como inhibidores de la proteina quinasa | |
| DOP2015000304A (es) | Inhibidores cristalinos de bromodominios | |
| CY1109998T1 (el) | Ενδυναμωτες υποδοχεων γλουταμινικου | |
| CU23779B7 (es) | Compuestos de pirazolina y su uso y composiciones farmacéuticas | |
| CL2011000544A1 (es) | Compuestos derivados de benzamida n sustituida por heterociclo, ligandos de los receptores cannabinoides; composicion farmaceutica; y su uso para tratar el dolor, entre otras enfermedades. | |
| NO20083246L (no) | Nye benzimidazolderivater som vanilloid-reseptor 1 (VRL) inhibitorer | |
| DE602006012713D1 (de) | Pyridinaminosulfonylsubstituierte benzamide als inhibitoren von cytochrom p450 3a4 (cyp3a4) | |
| NO20072005L (no) | Nye heterocykliske amider | |
| MX2019002615A (es) | Formas cristalinas de un inhibidor tipo lisil oxidasa 2 y metodos de realizacion. | |
| NO20080661L (no) | Nye cystein-protease-inhibitorer og deres terapeutiske anvendelser | |
| CL2007003043A1 (es) | Compuestos derivados de cromano; composicion farmaceutica que los comprende; y uso para el tratamiento de un trastorno psicotico, bipolar, depresivo y ansiedad entre otros. | |
| CL2007003396A1 (es) | Uso de agomelatina o n-[2-(7-metoxi-1-naftil)etil]acetamida para el tratamiento del sindrome de smith magenis; composicion farmaceutica que contiene agomelatina. | |
| DOP2006000024A (es) | Tiazolidinonas, su preparación y su uso como medicamento | |
| AR054779A1 (es) | N-(2,2-dimetilpropil)-6-{3-fluoro-5-[(3-isoxazolilamino)carbonil]-2-metilfenil}-3-piridinacarboxamida | |
| CL2004000730A1 (es) | Compuestos derivados de 4-[2-(fenilsulfanil sustituido)fenil]-1,2,3,6-tetrahidropiridina; composicion farmaceutica que los contiene; y su uso para el tratamiento de trastornos afectivos, tales como la depresion, trastornos de ansiedad, de ansiedad so | |
| CR9426A (es) | Utilizacion de agomelatina para la obtencion de medicamentos destinados al tratamiento de trastornos bipolares | |
| UY28993A1 (es) | Tetrahidroisoquinolinas sustituidas en calidad de inhibidores de mpm, procedimiento para su uso como medicamento.- | |
| CL2008002688A1 (es) | Formas polimorficas de (s)-2((4-benzofuranil)carbonilaminometil)-1-((4-(2-metil-5-(4-fluorofenil))tiazolil)carbonil)piperidina; composicion farmaceutica; y uso para el tratamiento o profilaxis de trastornos del sueño, depresion, ansiedad, trastornos relacionados con sustancias y trastornos relacionados con sustancias y trastornos alimentarios. | |
| CL2007003426A1 (es) | Compuestos derivados de dialquilaminoalquilo de pigavabina; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar trastornos afectivos, depresivos, de ansiedad. | |
| CL2008003047A1 (es) | Compuestos derivados de n-(2- fluoro-3-alquiloxifenil)metilquinolina-6- carboxamida; agente controlador de enfermedades de las plantas que contiene a dichos compuestos; metodo para controlar enfermedades de las plantas; uso de dichos compuestos; y compuestos intermediarios. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |